-
公开(公告)号：US20070160648A1
公开(公告)日：2007-07-12
申请号：US11710045
申请日：2007-02-23
申请人： Paul Ashton , Hong Guo , Thomas Smith
发明人： Paul Ashton , Hong Guo , Thomas Smith
IPC分类号： A61F2/02
CPC分类号： A61K9/0046 , G06Q50/22
摘要： Loss of hearing can be treated by implanting a sustained-release drug delivery device in the inner ear. The slow delivery of medication from the implanted device to the tissues of the ear, including the inner ear, can treat numerous conditions of the ear while avoiding the side effects associated with systemic administration.
摘要翻译： 可以通过在内耳中植入持续释放药物递送装置来治疗失聪。 从植入装置到包括内耳的组织的缓慢递送药物可以治疗耳朵的许多情况，同时避免与全身给药相关的副作用。
-
公开(公告)号：US20050025834A1
公开(公告)日：2005-02-03
申请号：US10877761
申请日：2004-06-25
申请人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
发明人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
IPC分类号： A61K9/00 , A61K9/50 , A61K31/382 , A61K31/485 , A61K31/542 , A61K9/14
CPC分类号： A61K38/385 , A61K9/0019 , A61K9/0024 , A61K9/0051 , A61K9/0092 , A61K9/5031 , A61K31/382 , A61K31/485 , A61K31/542
摘要： The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
摘要翻译： 本发明涉及缓释药物递送系统，包含所述系统的医疗装置及其使用和制造方法。 本发明的系统具有包括生物相容性固体和生物相容性流体组合物以实现期望的持续释放药物递送的生物可腐蚀药物递送装置。
-
公开(公告)号：US11026885B2
公开(公告)日：2021-06-08
申请号：US15147203
申请日：2016-05-05
申请人： Paul Ashton , Leigh T. Canham , Christian Barnett
发明人： Paul Ashton , Leigh T. Canham , Christian Barnett
IPC分类号： A61K9/00 , A61K9/14 , A61K38/17 , A61K38/28 , A61K38/47 , A61L27/02 , A61L27/54 , A61L27/56 , C07K16/22 , A61K39/395
摘要： This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
-
公开(公告)号：US20130101656A1
公开(公告)日：2013-04-25
申请号：US13612076
申请日：2012-09-12
申请人： Dongling Su , Paul Ashton , Jianbing Chen
发明人： Dongling Su , Paul Ashton , Jianbing Chen
IPC分类号： A61K47/48
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/0051 , A61K9/0092 , A61K9/06 , A61K31/196 , A61K31/382 , A61K31/485 , A61K31/542 , A61K47/55 , A61K47/60 , A61K47/6903
摘要： The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.
摘要翻译： 本发明提供了液体控释药物递送组合物，其在注射入体内时凝胶形成原位控制释放的药物植入物。 本发明的组合物的特征在于不溶于水的凝胶形成聚合物，其中溶解聚合物的聚乙二醇溶剂和待递送的药物。
-
公开(公告)号：US20080220062A1
公开(公告)日：2008-09-11
申请号：US11977148
申请日：2007-10-23
申请人： Paul Ashton
发明人： Paul Ashton
CPC分类号： A61K9/0019 , A61K9/0014 , A61K9/0024 , A61K9/0031 , A61K9/006
摘要： The invention relates to the treatment of localized pain by providing sustained release of an agent suitable for treating pain, methods for preparing and administering the agent, and methods of formulating and administering the agent as a pharmaceutical preparation. The agent can be locally administered to reduce systemic concentrations of the agent.
摘要翻译： 本发明涉及通过提供适于治疗疼痛的药剂的持续释放来治疗局部疼痛，制备和施用该药剂的方法，以及作为药物制剂的配制和施用方法。 可以局部施用该试剂以降低试剂的全身浓度。
-
公开(公告)号：US06936270B2
公开(公告)日：2005-08-30
申请号：US10139143
申请日：2002-05-02
IPC分类号： A61B17/56 , A61B17/00 , A61B17/064 , A61B17/16 , A61B17/80 , A61B17/82 , A61B17/86 , A61B17/88 , A61F2/30 , A61K9/00 , A61K31/58 , A61K38/00 , A61L31/16 , A61M31/00 , A61P19/02 , A61K2/02
CPC分类号： A61K9/0024 , A61B17/0642 , A61B17/1615 , A61B17/80 , A61B17/82 , A61B17/8615 , A61B17/8877 , A61B17/8886 , A61B2017/00004 , A61B2017/00429 , A61B2017/00955 , A61B2017/0647 , A61B2017/0648 , A61F2/30744 , A61F2002/30673 , A61F2002/30677 , A61L31/16 , A61L2300/222 , A61L2300/416 , A61L2300/602 , A61M31/002 , A61M2210/02
摘要： A therapeutically effective compound is locally administered by associating the compound with a piece of orthopedic hardware that is implanted at an appropriate site within a body. The compound is adapted, such as through a sustained release device, to administer an effective dosage continuously over an extended period of time. The compound may be administered, for example, to a joint of a mammal by intraarticularly implanting a sustained release device to deliver the therapeutically effective compound within a synovial capsule of the joint, such that synovial fluid concentration of the compound is greater than plasma concentration of the compound. A wide range of orthopedic hardware, such as bone screws and staples, may be adapted to use in the systems described herein to provide treatment for a variety of medical conditions.
摘要翻译： 通过将化合物与植入体内适当部位的整形外科硬件相结合来局部施用治疗有效的化合物。 化合物例如通过持续释放装置适于在长时间内连续施用有效剂量。 该化合物可以例如通过关节内植入持续释放装置来将哺乳动物的关节施用于在关节的滑膜内递送治疗有效化合物，使得该化合物的滑液浓度大于 化合物。 诸如骨螺钉和钉钉的各种矫形硬件可适于在本文所述的系统中使用以提供针对各种医疗状况的治疗。
-
37.发明申请公开(公告)号：US20170049703A1
公开(公告)日：2017-02-23
申请号：US15143283
申请日：2016-04-29
申请人： Christian Barnett , Paul Ashton , Leigh T. Canham
发明人： Christian Barnett , Paul Ashton , Leigh T. Canham
IPC分类号： A61K9/14 , C07K16/22 , A61K39/395 , A61K9/00
CPC分类号： A61K9/146 , A61K9/0048 , A61K9/0051 , A61K9/143 , A61K9/145 , A61K9/19 , A61K9/5031 , A61K38/42 , A61K39/3955 , A61K39/39591 , C07K16/22 , C07K2317/24
摘要： The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
摘要翻译： 本发明包括一种包含生物可腐蚀多孔硅基载体材料的组合物，其中载体材料携带至少一种大分子治疗剂和至少一种无定形糖，任选地还包含结晶抑制剂。 组合物可以在体外或体内用于递送治疗剂，优选以预定的时间段（例如多天，数周或数月）以受控的方式递送。 该组合物可用于治疗或预防患者如慢性疾病的病症。
-
公开(公告)号：US20120238994A1
公开(公告)日：2012-09-20
申请号：US13333743
申请日：2011-12-21
申请人： Martin Nazzaro , Josh York , Paul Ashton
发明人： Martin Nazzaro , Josh York , Paul Ashton
CPC分类号： A61L27/34 , A61K9/0051 , A61K9/0092 , A61K31/5575 , A61L27/54 , A61L31/10 , A61L31/16 , A61L2300/602 , A61L2300/606 , A61L2300/61 , Y10T29/49826 , C08L67/04 , C08L29/04
摘要： The invention provides a drug delivery device for latanoprost or latanoprost acid. The device has a core of latanoprost or latanoprost acid which is surrounded by an internal and external sheath. The external sheath has a first cap that is permeable to latanoprost or latanoprost acid. The first cap may comprise polyvinyl alcohol (PVA), and the PVA may be heat cured. In certain aspects, there are one or more additional caps on the ends of the sheaths formed from one or more polymers. In certain aspects, one or more portions of the drug delivery device is substantially impermeable to latanoprost or latanoprost acid. In certain aspects, the latanoprost or latanoprost acid elutes through the first cap into a biological environment. The invention further provides methods for manufacturing the drug delivery device.
摘要翻译： 本发明提供了拉坦前列素或拉坦前列素酸的药物递送装置。 该装置具有由内部和外部护套包围的拉坦前列素或拉坦前列素酸的核心。 外鞘具有对拉坦前列素或拉坦前列素酸可渗透的第一帽。 第一盖可以包括聚乙烯醇（PVA），并且PVA可以被热固化。 在某些方面，在由一种或多种聚合物形成的护套的端部上存在一个或多个另外的帽。 在某些方面，药物递送装置的一个或多个部分对于拉坦前列素或拉坦前列素酸是基本上不可渗透的。 在某些方面，拉坦前列素或拉坦前列素酸通过第一帽洗脱成生物环境。 本发明还提供了用于制造药物递送装置的方法。
-
公开(公告)号：US20120177695A1
公开(公告)日：2012-07-12
申请号：US13286788
申请日：2011-11-01
申请人： Paul Ashton , Leigh T. Canham , Christian Barnett
发明人： Paul Ashton , Leigh T. Canham , Christian Barnett
CPC分类号： A61K9/0051 , A61K9/0024 , A61K9/143 , A61K38/1709 , A61K38/28 , A61K38/47 , A61K39/3955 , A61L27/025 , A61L27/54 , A61L27/56 , A61L2400/12 , C07K16/22 , C12Y302/01017
摘要： This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
摘要翻译： 本发明公开了以可控方式递送治疗剂，特别是大分子如蛋白质和抗体的生物腐蚀性装置。 该装置包括浸渍有治疗剂的多孔硅基载体材料。 该装置可以在体外或体内用于递送治疗剂，优选以预定的时间段（例如多天，数周或数月）以受控的方式递送。 该装置可用于治疗或预防患者的病症如慢性疾病。
-
公开(公告)号：US20110165242A1
公开(公告)日：2011-07-07
申请号：US12870616
申请日：2010-08-27
申请人： Dongling Su , Paul Ashton , Jianbing Chen
发明人： Dongling Su , Paul Ashton , Jianbing Chen
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/0051 , A61K9/0092 , A61K9/06 , A61K31/196 , A61K31/382 , A61K31/485 , A61K31/542 , A61K47/55 , A61K47/60 , A61K47/6903
摘要： The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.
摘要翻译： 本发明提供了液体控释药物递送组合物，其在注射入体内时凝胶形成原位控制释放的药物植入物。 本发明的组合物的特征在于不溶于水的凝胶形成聚合物，其中溶解聚合物的聚乙二醇溶剂和待递送的药物。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.026 秒)
